07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

Antineoplastons: Phase II data

A U.S. Phase II trial in 19 evaluable patients with newly diagnosed anaplastic astrocytoma showed that ANP every 4 hours led to a complete response rate of 21% and a stable disease rate of 26%....
07:00 , Jun 1, 2009 |  BC Week In Review  |  Clinical News

Antineoplastons: Phase II data

Data from a Japanese Phase II trial in 65 MCRC patients who had undergone curative resection of hepatic metastases showed that Antineoplastons (ANP) therapy in combination with 5-fluorouracil (5-FU) produced an overall 5-year survival rate...
07:00 , May 18, 2009 |  BC Week In Review  |  Clinical News

Antineoplastons: Phase II data

Data from 80 evaluable patients in a Phase II trial showed that IV antineoplastons therapy resulted in complete or partial responses in 32% of patients and stable disease in 43%. Overall survival was 36% at...
07:00 , May 11, 2009 |  BC Week In Review  |  Clinical News

Antineoplastons: Final Phase II data

Final data from an open-label, U.S. Phase II trial in 16 children showed that IV antineoplastons therapy met the primary endpoint of achieving an objective response in at least 10% of patients (5 patients or...
08:00 , Jan 19, 2009 |  BC Week In Review  |  Clinical News

Antineoplastons regulatory update

Burzynski Research received an SPA from FDA for a Phase III trial to evaluate antineoplaston in combination with radiotherapy to treat newly-diagnosed diffuse intrinsic brainstem glioma in pediatric patients. The therapy combines injectable Atengenal (antineoplaston...